Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
RMTI's Cash-to-Debt is ranked higher than
99% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RMTI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 27.81 Max: No Debt
Current: No Debt
Equity-to-Asset 0.64
RMTI's Equity-to-Asset is ranked higher than
51% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RMTI: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
RMTI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.59  Med: 0.63 Max: 0.87
Current: 0.64
-0.59
0.87
Interest Coverage No Debt
RMTI's Interest Coverage is ranked higher than
99% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. RMTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RMTI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 6.14
Beneish M-Score: -2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -37.92
RMTI's Operating Margin % is ranked lower than
83% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. RMTI: -37.92 )
Ranked among companies with meaningful Operating Margin % only.
RMTI' s Operating Margin % Range Over the Past 10 Years
Min: -108.87  Med: -29.84 Max: -4.82
Current: -37.92
-108.87
-4.82
Net Margin % -37.16
RMTI's Net Margin % is ranked lower than
83% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. RMTI: -37.16 )
Ranked among companies with meaningful Net Margin % only.
RMTI' s Net Margin % Range Over the Past 10 Years
Min: -108.39  Med: -31.61 Max: -4.51
Current: -37.16
-108.39
-4.51
ROE % -34.28
RMTI's ROE % is ranked lower than
83% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. RMTI: -34.28 )
Ranked among companies with meaningful ROE % only.
RMTI' s ROE % Range Over the Past 10 Years
Min: -1304.41  Med: -34.36 Max: -8.96
Current: -34.28
-1304.41
-8.96
ROA % -23.02
RMTI's ROA % is ranked lower than
81% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. RMTI: -23.02 )
Ranked among companies with meaningful ROA % only.
RMTI' s ROA % Range Over the Past 10 Years
Min: -220.66  Med: -27.46 Max: -7.47
Current: -23.02
-220.66
-7.47
ROC (Joel Greenblatt) % -170.68
RMTI's ROC (Joel Greenblatt) % is ranked lower than
84% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. RMTI: -170.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RMTI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2678.13  Med: -260.69 Max: -52.63
Current: -170.68
-2678.13
-52.63
3-Year Revenue Growth Rate -12.90
RMTI's 3-Year Revenue Growth Rate is ranked lower than
87% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. RMTI: -12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RMTI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -23.2  Med: 2.7 Max: 32
Current: -12.9
-23.2
32
3-Year EBITDA Growth Rate -35.90
RMTI's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. RMTI: -35.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RMTI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.9  Med: -24.2 Max: 165.1
Current: -35.9
-52.9
165.1
3-Year EPS without NRI Growth Rate -35.90
RMTI's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. RMTI: -35.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RMTI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -20.6 Max: 109.9
Current: -35.9
0
109.9
GuruFocus has detected 5 Warning Signs with Rockwell Medical Inc $RMTI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RMTI's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

RMTI Guru Trades in

Q2 2015

RMTI Guru Trades in Q2 2015

Paul Tudor Jones 26,035 sh (+3.44%)
» More
Q3 2015

RMTI Guru Trades in Q3 2015

Paul Tudor Jones 49,916 sh (+91.73%)
» More
Q4 2015

RMTI Guru Trades in Q4 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:CKDXY, NAS:NBRV, NAS:ZGNX, OTCPK:ABSCF, NAS:RTRX, NAS:ALIM, OTCPK:FAMDF, AMEX:NNVC, NAS:OASM, OTCPK:PXSLY, NAS:PRPH, NAS:TNXP, AMEX:AXN, NAS:IMNP, OTCPK:CHEXF, OTCPK:SUWN, NAS:ALQA, NAS:NVGN, AMEX:CPHI, OTCPK:INNV » details
Traded in other countries:RWM.Germany,
Headquarter Location:USA
Rockwell Medical Inc is a biopharmaceutical company engaged in end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.

Top Ranked Articles about Rockwell Medical Inc

Rockwell Medical Announces Poster Presentation and Oral Presentation on Triferic at the 7th Congress of the International BioIron Society May 7 – 11, 2017
Rockwell Medical Files Definitive Proxy Materials
Rockwell Medical Announces Triferic® Poster Presentations at the National Kidney Foundation (NKF) Spring Clinical Meeting in Orlando, FL April 18-22, 2017
Rockwell Medical Files Preliminary Proxy Statement for Annual Meeting
Rockwell Medical Announces ESA Sparing, Compositions and Use Patent Allowed in China

ESA Sparing, Compositions and Use Claims Provide Long-Term Protection in China

WIXOM, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it received notice from the State Intellectual Property Office of the People's Republic of China (SIPO) that patent claims relating to ESA Sparing, Compositions and Use for Triferic have been accepted for grant in China. Triferic is the only FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients who suffer from anemia. 
The claims allowed in the patent application, entitled “Methods of Treating Iron Deficiency with Soluble Ferric Pyrophosphate” include composition of matter and use of soluble ferric pyrophosphate to reduce ESA usage using hemodialysis solution with the specific dose. The patent provides protection through February 2034.  Mr. Robert L. Chioini, Chairman and CEO of Rockwell stated, “We are thrilled to receive this important patent and the valuable IP protection it provides in the Chinese market. We view China as a key strategic dialysis market that we anticipate may become the world’s largest over the next several years.” About Triferic
Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, effectively maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and it is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Please visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information. About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Triferic® is a registered trademark of Rockwell Medical, Inc.
Michael Rice, Investor Relations; 646-597-6979

Read more...
Rockwell Medical Schedules Fourth Quarter & Year End 2016 Earnings Call

WIXOM, Mich., March 13, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold a conference call to discuss fourth quarter and year end 2016 financial results on Wednesday, March 15, 2017 at 4:30pm Eastern Time. 
This call is also being webcast and can be accessed at the Rockwell Medical Investor Relations web page.  You can join this call on: Date: Wednesday, March 15, 2017Time: 4:30pm ET Dial in number: 888-438-5453 International dial in: 719-457-2637 Passcode: 8360933 Webcast: http://ir.rockwellmed.com About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Triferic® is a registered trademark of Rockwell Medical, Inc.
Michael Rice, Investor Relations; 646-597-6979

Read more...
Rockwell Medical Announces One Poster and Two Oral Presentations on Triferic at Annual Dialysis Conference March 11th-14th in Long Beach, CA

WIXOM, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that poster and oral presentations for Triferic have been selected by the Annual Dialysis Conference for presentation at their Annual Meeting, March 11-14, 2017 in Long Beach, CA.  Triferic is the Company’s late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Triferic is the only FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients.
Presentation schedule at the ADC meeting: Poster Presentation:
Ferric Pyrophosphate Citrate (Triferic): One Month Intraperitoneal Toxicology and Toxicokinetic Study
Ajay Gupta MD, John Dillberger Ph.D., Raymond D. Pratt MD and Division of Nephrology, U of Cal Irvine, CA
Rockwell Medical, Inc., Wixom, MI, USA
Sunday, March 12 and Monday, March 13 at 12:00 – 1:00 PM PT
                    
Oral Presentation:
Pharmacokinetics of Triferic Administered IV and Via Dialysate
Raymond D Pratt, MD, Sarah Grimberg and Ajay Gupta, MD 
Rockwell Medical, Inc., Wixom, MI, USA
Monday, March 13 at 8:45 AM PT (Slide Forum II, Basic Science)
                    
Oral Presentation:
Pharmacokinetics (PK) of Triferic Administered IV to Healthy Volunteers: Modeling Diurnal Iron and Additivity of Triferic Iron
Raymond D. Pratt, MD, Mark Bush, Ph.D., Scott Brantley, Ph.D. and Ajay Gupta, MD 
Rockwell Medical, Inc., Wixom, MI, USA and Nuventra, Durham, NC
Monday, March 13 at 9:15 AM PT (Slide Forum II, Basic Science) The Annual Dialysis Conference convenes an international group of practitioners and researchers to discuss current developments in the field of dialysis. The conference is designed for health professionals involved in established dialysis programs, as well as those working in new and developing programs. About Triferic
Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, effectively maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and it is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Please visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information. About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Triferic® is a registered trademark of Rockwell Medical, Inc.
Michael Rice, Investor Relations; 646-597-6979

Read more...
Rockwell Medical Announces Nomination of David Domzalski to Board of Directors
WIXOM, Mich., March 02, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that David Domzalski, has been nominated to join the Company’s Board of Directors. Mr. Domzalski is nominated to replace Mr. Ken Holt, whose term is expiring. Mr. Holt has served the Rockwell Board for several years and will remain engaged through the end of his term.
“David has a proven track record at a senior level in the pharmaceutical industry,” said Robert L. Chioini, Founder, Chairman and CEO of Rockwell Medical. “He has extensive experience in building commercial organizations and launching products, which will be helpful as we commercialize Triferic globally. We are very pleased to have someone of David’s caliber join our Board of Directors and we look forward to the strategic contributions and insights he will bring.” Mr. Chioini also added, “Ken Holt has been a valuable member of our Board and served the Company loyally for many years and has contributed a great deal during his tenure. We thank Ken for his contributions and wish him the very best.”“I am excited to join the Rockwell Medical Board of Directors at this exciting time for the company,” said David Domzalski. “I look forward to working with the executive team and the Board and contributing to the successful launches of their drug products into the global marketplace.”David Domzalski is an accomplished healthcare and pharmaceutical executive with strategic and operational experience across key functional disciplines, including commercial operations, clinical development, manufacturing and product development, corporate financing, and business development. He has extensive experience in building and restructuring commercial organizations within multi-cultural environments of “start-up” and established corporations. He has a record of achievement in new product launches and life-cycle management across multiple therapeutic classes. He is highly successful in cultivating external partnerships and strategic alliances guided by strong interpersonal and negotiation skills. Mr. Domzalski has more than 20 years of industrial experience. David Domzalski currently serves as President of the U.S. subsidiary of Foamix Pharmaceuticals Inc., a position he has held since April 2014. Prior to his tenure at Foamix, Mr. Domzalski was Vice President of Sales & Marketing at LEO Pharma, Inc. where he led the efforts to design and build-out the U.S. commercial operations, overseeing approximately 200 employees across multiple functional areas. He successfully managed the turnaround of LEO Pharma’s psoriasis franchise from a 2-year prescription decline to an annual growth of 26%. He was responsible for the strategic re-launch of Taclonex® Topical Suspension, which resulted in Taclonex being reestablished as the number one brand in the category. Prior to LEO Pharma, Mr. Domzalski was the Senior Vice President and General Manager of the Women’s Health & Urology division of Azur Pharma, where he had full P&L responsibility for a start-up business unit. Before Azur, Mr. Domzalski spent 5 years from 2003 to 2008 as the Vice President of Sales & Marketing for Warner Chilcott, where he directed all commercial efforts for in-line brands focused on therapeutic areas of dermatology, women’s health and urology. His achievements at Warner Chilcott included the launch of four products within a twelve month period, including Taclonex for psoriasis and Doryx® Tablets for acne. He led the structural design, development and growth of the commercial team at Warner Chilcott from 150 to 500 employees. Earlier in his career, Mr. Domzalski held senior sales and marketing positions at Sanofi-Synthelabo, Pharmacia, Dendrite International and Parke-Davis. He earned a Bachelor of Arts in Economics and Political Science from Muhlenberg College. About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.Rockwell’s anemia drug Triferic is the only FDA approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally.Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.Triferic® is a registered trademark of Rockwell Medical, Inc.
Michael Rice, Investor Relations; 646-597-6979

Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.37
RMTI's PB Ratio is ranked lower than
78% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. RMTI: 8.37 )
Ranked among companies with meaningful PB Ratio only.
RMTI' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 7.36 Max: 950
Current: 8.37
1.73
950
PS Ratio 8.18
RMTI's PS Ratio is ranked lower than
71% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. RMTI: 8.18 )
Ranked among companies with meaningful PS Ratio only.
RMTI' s PS Ratio Range Over the Past 10 Years
Min: 0.47  Med: 2.77 Max: 14.67
Current: 8.18
0.47
14.67
EV-to-EBIT -19.86
RMTI's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. RMTI: -19.86 )
Ranked among companies with meaningful EV-to-EBIT only.
RMTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -80.4  Med: -14.8 Max: -1.2
Current: -19.86
-80.4
-1.2
EV-to-EBITDA -20.66
RMTI's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. RMTI: -20.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
RMTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1117.1  Med: -16.8 Max: -1.2
Current: -20.66
-1117.1
-1.2
Current Ratio 7.74
RMTI's Current Ratio is ranked higher than
86% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. RMTI: 7.74 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.96 Max: 10.46
Current: 7.74
0.49
10.46
Quick Ratio 6.54
RMTI's Quick Ratio is ranked higher than
84% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. RMTI: 6.54 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.61 Max: 9.49
Current: 6.54
0.35
9.49
Days Inventory 81.50
RMTI's Days Inventory is ranked higher than
69% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. RMTI: 81.50 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s Days Inventory Range Over the Past 10 Years
Min: 21.24  Med: 23.36 Max: 81.5
Current: 81.5
21.24
81.5
Days Sales Outstanding 43.79
RMTI's Days Sales Outstanding is ranked higher than
79% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. RMTI: 43.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.3  Med: 32.18 Max: 43.79
Current: 43.79
23.3
43.79
Days Payable 45.95
RMTI's Days Payable is ranked lower than
73% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. RMTI: 45.95 )
Ranked among companies with meaningful Days Payable only.
RMTI' s Days Payable Range Over the Past 10 Years
Min: 26.41  Med: 40.52 Max: 125.48
Current: 45.95
26.41
125.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.70
RMTI's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. RMTI: -8.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RMTI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -39  Med: -14.4 Max: 9.6
Current: -8.7
-39
9.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.93
RMTI's Price-to-Net-Cash is ranked higher than
52% of the 206 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.25 vs. RMTI: 15.93 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RMTI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.54  Med: 11.64 Max: 71
Current: 15.93
7.54
71
Price-to-Net-Current-Asset-Value 9.15
RMTI's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. RMTI: 9.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RMTI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.27  Med: 7.91 Max: 19.19
Current: 9.15
5.27
19.19
Price-to-Tangible-Book 8.51
RMTI's Price-to-Tangible-Book is ranked lower than
67% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. RMTI: 8.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RMTI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.59  Med: 6.49 Max: 25.25
Current: 8.51
3.59
25.25
Price-to-Median-PS-Value 2.95
RMTI's Price-to-Median-PS-Value is ranked lower than
84% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. RMTI: 2.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RMTI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.84 Max: 3.34
Current: 2.95
0.14
3.34
Earnings Yield (Greenblatt) % -5.04
RMTI's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. RMTI: -5.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RMTI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.7  Med: 0.7 Max: 0.7
Current: -5.04
-9.7
0.7

More Statistics

Revenue (TTM) (Mil) $53.29
EPS (TTM) $ -0.40
Beta2.08
Short Percentage of Float21.80%
52-Week Range $3.55 - 10.58
Shares Outstanding (Mil)52.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 61 69 72
EPS ($) -0.20 -0.05 0.03
EPS without NRI ($) -0.20 -0.05 0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Rockwell Medical Announces Poster Presentation and Oral Presentation on Triferic at the 7th Congress Apr 27 2017 
Rockwell Medical Files Definitive Proxy Materials Apr 21 2017 
Rockwell Medical Announces Triferic® Poster Presentations at the National Kidney Foundation (NKF) Apr 10 2017 
Rockwell Medical Files Preliminary Proxy Statement for Annual Meeting Apr 04 2017 
Rockwell Medical Announces ESA Sparing, Compositions and Use Patent Allowed in China Mar 28 2017 
Rockwell Medical Schedules Fourth Quarter & Year End 2016 Earnings Call Mar 13 2017 
Rockwell Medical Announces One Poster and Two Oral Presentations on Triferic at Annual Dialysis Conf Mar 06 2017 
Rockwell Medical Announces Nomination of David Domzalski to Board of Directors Mar 02 2017 
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 

More From Other Websites
Rockwell Medical Announces Poster Presentation and Oral Presentation on Triferic at the 7th Congress... Apr 27 2017
Richmond Brothers and Mark H. Ravich Send Letter to Rockwell Medical, Inc. Shareholders Apr 21 2017
Rockwell Medical Files Definitive Proxy Materials Apr 21 2017
Rockwell Medical (RMTI) Catches Eye: Stock Moves Up 12.1% Apr 20 2017
Rockwell Medical (RMTI) Looks Good: Stock Moves 5.9% Higher Apr 19 2017
Rockwell Medical Announces Triferic® Poster Presentations at the National Kidney Foundation (NKF)... Apr 10 2017
Richmond Brothers and Mark Ravich File Preliminary Proxy on Rockwell Medical, Inc. Apr 06 2017
Rockwell Medical Files Preliminary Proxy Statement for Annual Meeting Apr 04 2017
Rockwell Medical Announces ESA Sparing, Compositions and Use Patent Allowed in China Mar 28 2017
ETFs with exposure to Rockwell Medical, Inc. : March 27, 2017 Mar 27 2017
Richmond Brothers and Mark Ravich Comment on Rockwell Medical, Inc. Lawsuit Mar 22 2017
Rockwell Medical, Inc. :RMTI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Rockwell Medical, Inc. breached its 50 day moving average in a Bullish Manner : RMTI-US : March 17,... Mar 17 2017
Richmond Brothers and Mark Ravich Comment on Rockwell Medical, Inc. Earnings Mar 16 2017
Edited Transcript of RMTI earnings conference call or presentation 15-Mar-17 8:30pm GMT Mar 15 2017
Rockwell Medical reports 4Q loss Mar 15 2017
Rockwell Medical Reports Fourth Quarter Results Mar 15 2017
Rockwell Medical Schedules Fourth Quarter & Year End 2016 Earnings Call Mar 13 2017
Richmond Brothers and Mark Ravich Respond to Rockwell Medical, Inc. Lawsuit Mar 09 2017
Rockwell Medical Announces One Poster and Two Oral Presentations on Triferic at Annual Dialysis... Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)